LYNBROOK, N.Y., March 29, 2017 /PRNewswire/ -- BioSpecifics
Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that
originated and continues to develop collagenase based-therapies
with a first in class collagenase-based product collagenase
clostridium histolyticum (CCH) marketed as
XIAFLEX® in the U.S. and
Xiapex® in Europe, today announced that
management will present a corporate overview at the upcoming
16th Annual Needham Healthcare Conference on
Wednesday, April 5, 2017 at
8:00 a.m. ET in New York, NY.
A live webcast of the presentation can be accessed under "Events
and Presentation" in the Investors section of the Company's website
at www.biospecifics.com or at
http://wsw.com/webcast/needham80/bstc.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company
that has developed injectable collagenase for twelve clinical
indications to date. Injectable collagenase is marketed as XIAFLEX®
in the U.S. for the treatment of Dupuytren's contracture and
Peyronie's disease by BioSpecifics' partner, Endo International plc
(Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for
Peyronie's disease in Europe and
Australia. Endo is partnered with
Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and
Peyronie's disease outside the U.S. The XIAFLEX research and
development pipeline includes several additional promising
indications. BioSpecifics is managing the development of XIAFLEX
for uterine fibroids and plans to initiate clinical development in
the first quarter of 2017. For more information, please
visit www.biospecifics.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-16th-annual-needham-healthcare-conference-300431186.html
SOURCE BioSpecifics Technologies Corp.